IMGN632 stands as a noteworthy advancement in cancer therapeutics, being a humanized IgG1 monoclonal antibody meticulously engineered for CD123, coupled with a pioneering DNA-alkylating indolinobenzodiazepine pseudodimer (IGN) (Figure 2). This evidence concerns the gene IL3RA and cancer.